Product Description
SYN-020 is a recombinant version of bovine Intestinal Alkaline Phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery. The diverse mechanisms of IAP action indicate that SYN-020 may have utility in a broad range of therapeutic indications stemming from inflammation of the GI tract. In addition, SYN-020 may potentially diminish low-grade systemic inflammation, which is believed to exacerbate metabolic syndrome and accelerate the progression of diseases associated with aging. (Sourced from: https://www.syntheticbiologics.com/product-pipeline/syn-020)
Mechanisms of Action: IAP Replacer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Theriva Biologics, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Enteritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SB-1-020-002 | P1 |
Completed |
Enteritis |
2022-02-22 |
50% |
2023-03-24 |
Primary Endpoints |
| SB-1-020-001 | P1 |
Completed |
Enteritis |
2021-05-18 |
12% |
2023-03-24 |